Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).
Novavax received the green light from the Food ... In May, it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine.
U.S. regulators have cleared a third updated Covid-19 vaccine for this fall, shots made by Novavax. Already, Pfizer and Moderna are shipping shots modified to better match more recent strains of ...
AND IF YOU DON’T WANT TO GET AN MRNA VACCINE, YOU CAN ALSO GET NOVAVAX, WHICH IS A PROTEIN VACCINE. OKAY, ANY ADVICE FOR THOSE WHO ARE THINKING, YES, LET’S GET IT. AND WE DON’T HAVE ANY RISK ...
The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 ...
Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer ...
Health Canada authorized Novavax’s updated COVID-19 vaccine that protects against currently circulating variants of the virus on Thursday. The protein-based vaccine, called Nuvaxovid ...
Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback